Eli Lilly’s October 2024 research collaboration with Peptron granted only a non-exclusive, research-use license for SmartDepot’s ultrasonic spray-dried microsphere platform, which enables sustained-release injectable peptides lasting weeks to months. Subsequent reports indicate Lilly validated the technology yet pivoted toward competing sustained-release options such as Camurus and oral formulations for its obesity pipeline, with no public commercial licensing, technology-transfer, or binding rights agreement announced through mid-August 2026. With roughly eight weeks left before resolution and no recent catalysts such as FDA filings, partnership expansions, or executive statements, traders assign an 87.5% implied probability to “No,” reflecting the absence of deal momentum and Lilly’s demonstrated preference for alternative delivery technologies.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% szansa
$11,264 Wol.
$11,264 Wol.
Oct 7, 2026
13% szansa
$11,264 Wol.
$11,264 Wol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research collaboration with Peptron granted only a non-exclusive, research-use license for SmartDepot’s ultrasonic spray-dried microsphere platform, which enables sustained-release injectable peptides lasting weeks to months. Subsequent reports indicate Lilly validated the technology yet pivoted toward competing sustained-release options such as Camurus and oral formulations for its obesity pipeline, with no public commercial licensing, technology-transfer, or binding rights agreement announced through mid-August 2026. With roughly eight weeks left before resolution and no recent catalysts such as FDA filings, partnership expansions, or executive statements, traders assign an 87.5% implied probability to “No,” reflecting the absence of deal momentum and Lilly’s demonstrated preference for alternative delivery technologies.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 5, 2026, 8:02 PM ET
Wolumen
$11,264Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research collaboration with Peptron granted only a non-exclusive, research-use license for SmartDepot’s ultrasonic spray-dried microsphere platform, which enables sustained-release injectable peptides lasting weeks to months. Subsequent reports indicate Lilly validated the technology yet pivoted toward competing sustained-release options such as Camurus and oral formulations for its obesity pipeline, with no public commercial licensing, technology-transfer, or binding rights agreement announced through mid-August 2026. With roughly eight weeks left before resolution and no recent catalysts such as FDA filings, partnership expansions, or executive statements, traders assign an 87.5% implied probability to “No,” reflecting the absence of deal momentum and Lilly’s demonstrated preference for alternative delivery technologies.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Wolumen
$11,264Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 research collaboration with Peptron granted only a non-exclusive, research-use license for SmartDepot’s ultrasonic spray-dried microsphere platform, which enables sustained-release injectable peptides lasting weeks to months. Subsequent reports indicate Lilly validated the technology yet pivoted toward competing sustained-release options such as Camurus and oral formulations for its obesity pipeline, with no public commercial licensing, technology-transfer, or binding rights agreement announced through mid-August 2026. With roughly eight weeks left before resolution and no recent catalysts such as FDA filings, partnership expansions, or executive statements, traders assign an 87.5% implied probability to “No,” reflecting the absence of deal momentum and Lilly’s demonstrated preference for alternative delivery technologies.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania